Meitheal Pharmaceuticals Inc. through its parent company Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. announced an exclusive licensing agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to commercialize three insulin biosimilars ? insulin aspart, insulin lispro, and insulin glargine in the U.S. NKF has exclusive development and commercial rights for the three compounds from partner THDB and intends for Meitheal to commercialize such products in the U.S. Under the terms of the agreement, Meitheal, through its parent company, will receive exclusive rights to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine in the U.S. upon approval by the FDA, which is estimated to be on or around 2026. THDB and NKF entered into strategic cooperation and will be jointly responsible for the development and supply of the three products.

Upon approval, THDB, NKF and Meitheal will receive royalties on all product sales in the United States.